Rationale for Clinical Development
BCMA is a promising target for the treatment of multiple myeloma using various investigational modalities, such as a TCE, because it is universally expressed on the surface of malignant and non-malignant plasma cells and is essential for the survival of these cells.1,3,4 Preclinical studies have shown that anti-BCMA TCEs may cross-link T cells with BCMA-expressing cells, including malignant myeloma cells, potentially leading to increased immune antitumor activity via redirected killing of myeloma and healthy plasma cells by autologous T cells.1,2 Preclinical studies are ongoing to optimize, improve, and assess the potential benefits and risks of CC-93269 as a single agent therapy or in combination with other therapies in multiple myeloma.